
Sign up to save your podcasts
Or


Christopher Bunick, MD, PhD, LiVDerm faculty and member of the SBS Planning Committee, shares key takeaways from his session at the SBS 2022 event regarding IL-13 inhibitors for treatment of AD and the underlying disease pathogenesis.
By LivDerm5
66 ratings
Christopher Bunick, MD, PhD, LiVDerm faculty and member of the SBS Planning Committee, shares key takeaways from his session at the SBS 2022 event regarding IL-13 inhibitors for treatment of AD and the underlying disease pathogenesis.

135 Listeners

25,864 Listeners

112,574 Listeners

1,146 Listeners

16 Listeners

8,995 Listeners

195 Listeners

35 Listeners

133 Listeners

29,173 Listeners

52 Listeners

85 Listeners

6 Listeners

6 Listeners

33 Listeners